Of particular interest is that this dysregulated IFN response appears to occur in the upper airways and in the early stages of COVID-19, followed by exuberant IFN production in the context of a hyperactive inflammatory response that occurs later in the lungs (Eskandarian Boroujeni et al., 2022). This evidence concerns the gene IFNA1 and COVID-19.